HUTCHMED held its Annual General Meeting on 12 May 2026, with every ordinary and special resolution securing clear approval through a poll vote.

The resolution to adopt the 2025 audited financial statements drew 440.15 million votes in favour—representing 99.9998% of the ballots cast—confirming broad shareholder endorsement of the company’s results and reporting.

Director re-elections received strong backing, with support ratios ranging from 93.05% for Dr. Dan Eldar to 99.99% for Dr. Chaohong Hu and Professor Daniel Tan. All nine nominees therefore continue on the board.

Shareholders re-appointed PricewaterhouseCoopers and PricewaterhouseCoopers Zhong Tian LLP as independent auditors for Hong Kong and U.S. reporting, respectively. The motion passed with 89.73% approval (394.94 million votes for, 45.20 million against).

A special resolution granting directors a general mandate to issue additional shares won 99.99% support, while a companion mandate to repurchase shares achieved 99.99% approval.

Crucially, the 2026 Share Option Scheme—which underpins long-term employee incentives—was cleared with 90.16% of votes cast (396.86 million in favour).

The meeting was attended by all directors except Ms. Ling Yang and Professor Tony Mok, who had prior overseas commitments. Total shares entitled to vote stood at 872.34 million, with no treasury shares outstanding. Computershare Investor Services (Jersey) Limited served as scrutineer for the poll.